USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Omm Scientific, Inc
Address:
2600 N Stemmons Freeway, Suite 129
Dallas, TX
EIN:
593785219
DUNS:
610369535
Number of Employees:
6
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $378,941.00 3
STTR Phase I $267,231.00 2
STTR Phase II $749,999.00 1

Award List:

Improved Methodology for RNA Synthesis

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$99,014.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this application is to show that 2'O-(N,N-dimethylthiocarbamate) (DMTC) protected monomers (see Fig. 1) can be used as effectively in the SPS of oligo-RNAs as the commercial ones and that an siR NA will be as biologically active as one… More

Ratiometric SPCE Detection of miRNA

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$167,231.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Fluorescence technologies are key research tools in the life sciences, biotechnology, medical diagnostics, forensics, and other fields. Fluorescence-based measurements include ELISA, PCR, microarray gene expression chip s, other medical diagnostics, forensics… More

SBIR TOPIC 255, PHASE I: DEVELOPMENT OF ANTICANCER VATPASE INHIBITORS

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$199,931.00
Agency:
HHS
Principal Investigator:
Donald Stewart – 214-350-9156
Abstract:
Invasive, metastatic, and/or drug resistant cancers are responsible for most cancer deaths. Development of a drug that blocks these phenotypes to improve outcomes is the ultimate objective. The specific means is by inhibiting the acidification of extra-cellular and extra-tumoral environments that… More

Selective Oxidation of Heterocyclic Amines

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$100,000.00
Agency / Branch:
DOD / USAF
Principal Investigator:
Edward R. Biehl, Professor of Chemistry – (214) 768-1280
Research Institution:
Southern Methodist University
RI Contact:
Alicia Brossette
Abstract:
ABSTRACT: New energetic materials are needed for use in explosives and propellants that have a very powerful energy release yet are insensitive to handling. Safer materials that also allow development of lighter weight, longer range missiles and higher performance explosives are needed. One class… More

Selective Oxidation of Heterocyclic Amines

Award Year / Program / Phase:
2013 / STTR / Phase II
Award Amount:
$749,999.00
Agency:
DOD
Principal Investigator:
Edward R. Biehl, Professor of Chemistry – (214) 768-1280
Research Institution:
Southern Methodist University
RI Contact:
Alicia Brossette
Abstract:
ABSTRACT: This proposal sets out a plan to continue the method development for selective chemical oxidization of one amine of a polyamino, multi-heterocyclic class of energetic materials. The approach is based on screening one substrate (DAAzF) with many different oxidants under a variety of… More

Rapid Feasibility Studies for Novel Routes to Direct CL-20 Intermediates

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$79,996.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Donald Stewart, President&CEO – (214) 350-9156
Abstract:
The overall technical objective is to identify one or more promising synthetic methods for the preparation of a direct intermediate to CL-20 that uses commodity reagents and enable CL-20 to be prepared at a price of $150/lb. The intermediate will likely be a tetra- or hexa-acyl hexaazaisowurtzitane… More